Artemether + Lumefantrine is a fixed-dose combination therapy commonly used to treat uncomplicated malaria caused by Plasmodium falciparum. As a cornerstone of artemisinin-based combination therapies (ACTs), it is endorsed by the World Health Organization and included on its List of Essential Medicines.

Artemether + Lumefantrine: Combination Therapy for Malaria

What’s in the Combination?

  • Artemether:
    • Derived from artemisinin, a compound from the sweet wormwood plant.
    • Rapidly clears parasites from the bloodstream.
    • Has a short half-life (about 1–2 hours), making it fast-acting.
  • Lumefantrine:
    • A synthetic compound structurally related to older antimalarials.
    • Works more slowly but remains in the body longer (half-life: 3–6 days).
    • Clears any remaining parasites and helps prevent relapse or resistance.

How It Works

  • Artemether: Destroys parasites by generating toxic free radicals that damage cell membranes and essential proteins.
  • Lumefantrine: Interferes with parasite metabolism by binding to heme, disrupting nucleic acid and protein synthesis.

Indications for Use

  • Specifically used for acute, uncomplicated malaria caused by P. falciparum.
  • Often prescribed in regions with chloroquine resistance.

Dosing Guidelines

  • Standard regimen: 6 doses taken over 3 days.
  • Adults & children ≥35 kg: 4 tablets per dose (each tablet contains 20 mg artemether + 120 mg lumefantrine).
  • Children <35 kg: Dose is adjusted by weight.
  • Must be taken with a fatty meal or milk to improve lumefantrine absorption.

Possible Side Effects

  • Common:
    • Headache
    • Nausea and vomiting
    • Abdominal discomfort
    • Dizziness
    • Fatigue.
  • Rare but Serious:
    • QT interval prolongation (can cause heart rhythm disturbances)
    • allergic reactions including rash or swelling.

Contraindications & Cautions

  • Known hypersensitivity to either component.
  • Severe malaria (requires injectable treatment).
  • Heart rhythm issues, especially prolonged QT interval.
  • Liver or kidney dysfunction.
  • Pregnancy, especially during the first trimester (unless no alternatives exist).

Drug Interactions

  • Inhibitors of CYP3A4 (e.g., ketoconazole, protease inhibitors): May raise lumefantrine levels.
  • Inducers of CYP3A4 (e.g., rifampin, carbamazepine): Can reduce the drug’s effectiveness.
  • Other QT-prolonging drugs (e.g., macrolides, antipsychotics): May increase risk of cardiac side effects.

Important Takeaways

  • Effective against chloroquine-resistant strains of P. falciparum.
  • Should not be used for malaria prevention (prophylaxis).
  • Combining artemether with lumefantrine reduces resistance risk.
  • Proper adherence and dietary intake are key for effectiveness.